Regeneron Pharmaceuticals, Inc. (LON:0R2M)
795.78
-12.37 (-1.53%)
At close: Jan 9, 2026
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.75B USD in the quarter ending September 30, 2025, with 0.90% growth. This brings the company's revenue in the last twelve months to $14.25B, up 2.89% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.25B
Revenue Growth
+2.89%
P/S Ratio
5.75
Revenue / Employee
$943.19K
Employees
15,106
Market Cap
60.96B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Regeneron Pharmaceuticals News
- 1 day ago - Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Nasdaq
- 2 days ago - Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News - GuruFocus
- 2 days ago - Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Benzinga
- 3 days ago - REGN Crosses Above Average Analyst Target - Nasdaq
- 3 days ago - Regeneron Just Moved From Underperform To Buy - Here's Why - Benzinga
- 3 days ago - Regeneron Just Moved From Underperform To Buy - Here's Why - Benzinga
- 3 days ago - Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. - Barron's
- 3 days ago - Regeneron (REGN) Upgraded to Buy by BofA Securities - GuruFocus